PRATOSARTAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H26N6O
Molecular Weight	426.5135
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=O)CCCC2

InChI

InChIKey=KCTFTBCZZUBAKN-UHFFFAOYSA-N

InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30)

HIDE SMILES / InChI

Molecular Formula	C25H26N6O
Molecular Weight	426.5135
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18360048 | https://adisinsight.springer.com/drugs/800002623 | https://www.medchemexpress.com/Pratosartan.html

Pratosartan is an orally active angiotensin II type 1 receptor blocker. It is being developed for the treatment of hypertension. Pratosartan was efficacious throughout the long-term study, without serious adverse effects. Pratosartan significantly decreased serum total cholesterol in patients with hypercholesterolemia and uric acid in patients with hyperuricemia. It may have beneficial effects on hypertensive patients with some metabolic disorders. Pratosartan is still in phase III development in South Korea and phase II in Japan for hypertension.

Approval Year

PubMed

Title	Date	PubMed
Gateways to clinical trials. July-August 2008.	2008-10-14	18850047
Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.	2008-03	17674156
Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients.	2008-02	18360048
Effects of angiotensin II receptor blockers on renal handling of uric acid in rats.	2008	18762713
Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.	2007-01	17043154
Synthesis and pharmacological activity of the metabolites of Pratosartan.	2006-06	16755044
Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3h-cycloheptimidazol-4-ones and 2-alkyl-3h-cycloheptimidazol-4-ones.	2006-05	16651773
Antihypertensive effect of chronic KT3-671, a structurally new nonpeptide angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats.	1995-11	8699629

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:09:29 GMT 2025` Edited by `admin` on `Mon Mar 31 18:09:29 GMT 2025`
Record UNII	66VLQ6E6DL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PRATOSARTAN

Official Name

English

DA-727

Preferred Name

English

KT3-671

Code

English

Pratosartan [WHO-DD]

Common Name

English

pratosartan [INN]

Common Name

English

PRATOSARTAN [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66930